These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31642175)

  • 1. Osimertinib 160 mg daily for advanced non-small cell lung cancer with leptomeningeal metastasis: A case report.
    Tsang MW
    Asia Pac J Clin Oncol; 2019 Oct; 15 Suppl 6():5-7. PubMed ID: 31642175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.
    Saboundji K; Auliac JB; Pérol M; François G; Janicot H; Marcq M; Dubos-Arvis C; Renault A; Guisier F; Odier L; Gervais R; Chouaïd C
    Target Oncol; 2018 Aug; 13(4):501-507. PubMed ID: 30039345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation.
    Hu X; Chen W; Li X; Zhao C; Zhang C; Xiong F; Wu H
    Ann Palliat Med; 2019 Nov; 8(5):525-531. PubMed ID: 31865717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.
    Wang X; Cai J; Zeng Z; Liu A
    BMC Cancer; 2021 Jul; 21(1):873. PubMed ID: 34330231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in targeted therapy in non-small cell lung cancer with actionable mutations and leptomeningeal metastasis.
    Li D; Song Z; Dong B; Song W; Cheng C; Zhang Y; Zhang W
    J Clin Pharm Ther; 2022 Jan; 47(1):24-32. PubMed ID: 34309914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world data on treatment outcomes in
    Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer.
    Nanjo S; Hata A; Okuda C; Kaji R; Okada H; Tamura D; Irie K; Okada H; Fukushima S; Katakami N
    Br J Cancer; 2018 Jan; 118(1):32-37. PubMed ID: 29190637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.
    Ahn MJ; Han JY; Kim DW; Cho BC; Kang JH; Kim SW; Yang JC; Mitsudomi T; Lee JS
    Cancer Res Treat; 2020 Jan; 52(1):284-291. PubMed ID: 31345012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
    van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
    Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete remission in leptomeningeal metastasis of NSCLC with rare EGFR-SEPT14 fusion treated with osimertinib combined with intrathecal chemotherapy with pemetrexed.
    Zheng S; Li H; Feng J; Jiang C; Lin Y; Xie Y; Yu T; Qian X; Yin Z
    Anticancer Drugs; 2022 Jan; 33(1):e795-e798. PubMed ID: 34486539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
    Wang M; Zhu F; Luo N; Li M; Qi Y; Wang M
    Medicine (Baltimore); 2021 Nov; 100(44):e27727. PubMed ID: 34871271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
    Liu J; Jin B; Su H; Qu X; Liu Y
    BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
    Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T;
    Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
    Wu YL; Ahn MJ; Garassino MC; Han JY; Katakami N; Kim HR; Hodge R; Kaur P; Brown AP; Ghiorghiu D; Papadimitrakopoulou VA; Mok TSK
    J Clin Oncol; 2018 Sep; 36(26):2702-2709. PubMed ID: 30059262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report.
    Chalmers A; Jensen L; Akerley W
    Lung Cancer; 2017 Dec; 114():68-69. PubMed ID: 29173769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.
    Yang JCH; Kim SW; Kim DW; Lee JS; Cho BC; Ahn JS; Lee DH; Kim TM; Goldman JW; Natale RB; Brown AP; Collins B; Chmielecki J; Vishwanathan K; Mendoza-Naranjo A; Ahn MJ
    J Clin Oncol; 2020 Feb; 38(6):538-547. PubMed ID: 31809241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A non-small cell lung cancer (NSCLC) patient with leptomeningeal metastasis harboring rare epidermal growth factor receptor (EGFR) mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report.
    Shan CG; Wang H; Lin T; Liu D; Wen L; Chen ZJ; Zhen JJ; Lai MY; Zhang L; Zou X; Hong WP; Cai LB
    Ann Palliat Med; 2021 May; 10(5):5897-5901. PubMed ID: 33977730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.